JP2025506098A5 - - Google Patents

Info

Publication number
JP2025506098A5
JP2025506098A5 JP2024543285A JP2024543285A JP2025506098A5 JP 2025506098 A5 JP2025506098 A5 JP 2025506098A5 JP 2024543285 A JP2024543285 A JP 2024543285A JP 2024543285 A JP2024543285 A JP 2024543285A JP 2025506098 A5 JP2025506098 A5 JP 2025506098A5
Authority
JP
Japan
Prior art keywords
larinepag
radiation
measured
pattern
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/013032 external-priority patent/WO2023158634A1/en
Publication of JP2025506098A publication Critical patent/JP2025506098A/ja
Publication of JP2025506098A5 publication Critical patent/JP2025506098A5/ja
Pending legal-status Critical Current

Links

JP2024543285A 2022-02-15 2023-02-14 結晶質プロスタサイクリン(ip)受容体アゴニストおよびその使用 Pending JP2025506098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310469P 2022-02-15 2022-02-15
US63/310,469 2022-02-15
PCT/US2023/013032 WO2023158634A1 (en) 2022-02-15 2023-02-14 Crystalline prostacyclin (ip) receptor agonist and uses thereof

Publications (2)

Publication Number Publication Date
JP2025506098A JP2025506098A (ja) 2025-03-07
JP2025506098A5 true JP2025506098A5 (enExample) 2026-02-20

Family

ID=87578956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543285A Pending JP2025506098A (ja) 2022-02-15 2023-02-14 結晶質プロスタサイクリン(ip)受容体アゴニストおよびその使用

Country Status (9)

Country Link
US (2) US12098116B2 (enExample)
EP (1) EP4479374A1 (enExample)
JP (1) JP2025506098A (enExample)
KR (1) KR20240149924A (enExample)
CN (1) CN118922402A (enExample)
AU (1) AU2023222747A1 (enExample)
CA (1) CA3248736A1 (enExample)
IL (1) IL314717A (enExample)
WO (1) WO2023158634A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
IL320516A (en) 2022-10-31 2025-06-01 United Therapeutics Corp Methods for treating pulmonary hypertension
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945530A1 (de) 1979-11-10 1981-06-04 Chemische Werke Hüls AG, 4370 Marl Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide
JPH03160438A (ja) 1989-11-20 1991-07-10 Konica Corp ハロゲン化銀カラー写真感光材料
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
JPH06329598A (ja) 1993-05-19 1994-11-29 Daicel Chem Ind Ltd エステルの製造方法
DE4318889A1 (de) 1993-06-07 1994-12-08 Bayer Ag Verfahren zur Herstellung von organischen Carbamaten
KR100383305B1 (ko) 1994-03-10 2003-11-01 후지사와 야꾸힝 고교 가부시키가이샤 프로스타글란딘i₂작용물질로서의나프탈렌유도체
JPH11269138A (ja) 1998-03-20 1999-10-05 Mitsubishi Paper Mills Ltd 有機塩基発生剤
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
YU68102A (sh) 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
TWI316055B (enExample) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
AU2002322585A1 (en) 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
NZ531153A (en) 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN1735598A (zh) 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
EP1603878B1 (en) 2003-02-10 2013-01-02 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
BRPI0414630A (pt) 2003-09-22 2006-11-07 Hoffmann La Roche derivados ciclohexìlicos substituìdos com aminoalquilamida
JP4402413B2 (ja) 2003-09-29 2010-01-20 財団法人21あおもり産業総合支援センター U字型化合物およびこれを含む液晶組成物
DE102004006785A1 (de) 2004-02-11 2005-09-08 Mayr, Herbert, Prof. Dr. Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
JP4792731B2 (ja) 2004-11-12 2011-10-12 Dic株式会社 重合性液晶組成物及び当該組成物の硬化物
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
JP2007161867A (ja) 2005-12-14 2007-06-28 Toyo Ink Mfg Co Ltd インキ組成物
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
CN110003123B (zh) 2008-03-18 2023-06-23 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
AU2009325117C1 (en) 2008-11-26 2014-12-18 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2370413B1 (en) 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
WO2011037613A1 (en) 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
MX394186B (es) 2014-10-23 2025-03-24 Arena Pharm Inc Metodo de tratamiento de afecciones relacionadas con el receptor pgi2
KR20230021186A (ko) 2016-11-10 2023-02-13 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
JP7343478B2 (ja) 2017-08-07 2023-09-12 アレーナ ファーマシューティカルズ,インク. 処置の方法
KR20210040837A (ko) 2018-05-16 2021-04-14 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
EP4493540A4 (en) 2022-03-17 2026-02-18 United Therapeutics Corp RALINEPAG MEDICATIONS AND THEIR USES

Similar Documents

Publication Publication Date Title
KR102150383B1 (ko) 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법
RU2735547C2 (ru) Фармацевтическая композиция, содержащая 2-{ 4-[n-(5,6-дифенилпиразин-2-ил)-n-изопропиламино]бутилокси} -n-(метилсульфонил)ацетамид
CA2687924A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2025511847A5 (enExample)
JP2009534373A5 (enExample)
JP2023550428A5 (enExample)
JP2019509268A5 (enExample)
JP2024504392A5 (enExample)
JP2025506374A5 (enExample)
US9504672B2 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
CN107661302A (zh) 一种口服固体制剂及其应用
JPH0681723B2 (ja) 非−白金抗癌薬によりひき起こされる嘔吐の軽減用治療剤
JP2005529084A5 (enExample)
JP2024542840A5 (enExample)
CN107188890B (zh) 一种结晶形式的无引湿性原儿茶酸黄连素一水合物
WO2020238885A1 (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的治疗方法
JP2025516683A5 (enExample)
WO2009089702A1 (en) Stable 6-methoxy-2',3'-dideoxyguanosine, method for preparing the same and pharmaceutical composition containing the same
JP2024506942A5 (enExample)
RU2018135072A (ru) Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения
CN100577159C (zh) 一种用于治疗心脑血管疾病的杨梅素分散片及其制备方法
JP2019509286A5 (enExample)
Abdou Sweet co-crystals for pediatric drugs formulation
JPS5970611A (ja) 医薬組成物
JP7752443B2 (ja) クジノシドa化合物の結晶、その薬物組成物および応用